China's Cellular Biomedicine spikes on early CAR-T data

Shanghai drug developer Cellular Biomedicine ($CBMG) reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday. The company, working alongside Chinese PLA General Hospital, is developing an engineered T cell therapy, or CAR-T, to treat Hodgkin's lymphoma. In a trial on 7 patients with late-stage lymphoma, the treatment stabilized the disease in three subjects and charted a partial response in two of them, Cellular Biomedicine said. Release

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.